# Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

> **NCT03710460** · PHASE4 · UNKNOWN · sponsor: **University of Guadalajara** · enrollment: 33 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin plus Metformin XR
- **DRUG:** Metformin XR

## Key facts

- **NCT ID:** NCT03710460
- **Lead sponsor:** University of Guadalajara
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2023-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710460, "Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03710460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*